Abstracts

HIV Infections in Novel CD1a Cells From Human Vaginal Mucosa

Transfer across mucosal surfaces, such as the vaginal mucosa, account for the majority of new HIV-1 infections in the world.  The identity and susceptibility of potential target cells in the vaginal mucosa remain unclear. Skin and vaginal cells were obtained from women undergoing elective reduction mammoplasties and vaginal repairs respectively.  Discontinuous density gradients were used…

Reduced Rectal HIV RNA After Peg-IFN-a2b Added to ART Together With ART Interruption

The effects of Peg-IFN-a2b immunotherapy on gut tissue HIV-1 RNA remain unknown. We hypothesized that in antiretroviral therapy (ART) chronically suppressed HIV-1+ individuals addition of Peg-IFN-a2b to ART, including of a short ART interruption (to induce HIV reactivation), would decrease rectal tissue HIV levels by triggering anti-HIV mechanisms. 20 ART chronically suppressed (<50 copies/ml) HIV-1+…

Acute HIV Treatment Reverses CD8 T Cell Activation, Exhaustion, and Apoptosis

Despite viral suppression with cART, persistent inflammation contributes to pathogenesis and morbidity. We hypothesized that treatment during acute HIV infection (AHI) with an integrase inhibitor based regimen would decrease cellular activation, exhaustion, and apoptosis compared with subjects treated in chronic infection. Subjects identified in AHI (n= 18, Fiebig stages I-IV), were treated with tenofovir/emtricitabine and…

Increased Innate Function Following HIV-1 Suppression Is Linked to Epigenetic Changes

HIV-1 infection leads to both profound immune suppression and pathologic inflammation. While adaptive immune dysfunction has been extensively studied, less is known about innate immunity in the context of HIV-1. Based on the broad pathogen susceptibility in progressive HIV-1, we hypothesized that there would be aberrant innate responses. We tested innate function and investigated the…

Inhibition of P2X7 Enhances T-Cell Potential of CD34 in HIV+ c-ART Nonresponders

Although many factors are known to limit CD4 T-cell recovery during HIV infection, the impact of alteration in T-cell lymphopoiesis remains poorly understood. We hypothesize that deficient T-cell differentiation from CD34 hematopoietic progenitors (HP) could, at least partially, explain poor CD4 levels restoration under c-ART in HIV+ patients. PBMC were obtained from HIV+ immune responders…

Maraviroc and Immune Recovery in Advanced AIDS (CD4

In the CADIRIS trial 276 ART naïve patients with CD4 <100/uL were randomized to receive maraviroc (MVC) or placebo added to a standard ART regimen to evaluate the effects of CCR5 antagonism on occurrence of IRIS. No effect was demonstrable (Sierra-Madero Lancet HIV 2014). This substudy reports dynamics of phenotypic and functional cellular restoration upon…